New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- Cleave Biosciences
- 866 Malcolm, Suite 100
- Burlingame CA, 94010
- UNITED STATES
Cleave Biosciences is discovering and developing novel small molecule therapies for difficult-to-treat cancers by targeting protein homeostasis through the ubiquitin proteasome and autophagy systems, an area of unrealized potential. Cleave is using molecular profiling approaches with the goal of identifying patient subsets most likely to benefit from each of its targeted drugs.